1.Correlation between Aurora kinase and tumor
Yue ZHANG ; Bin ZHANG ; Xuchen CAO
Journal of International Oncology 2011;38(6):406-408
The Aurora kinase family of serine/threonine kinases plays an important role in chromosome alignment,segregation and cytokinesis during mitosis.Overexpression of Aurora kinases has been observed in a variety of human solid tumors and hematological malignancies.Aberrant expression of Aurora kinase can interrupt the function of the checkpoint in mitosis,lead to instability of genetic substance and induce tumorigenesis.
2.Effects of CD44 in cancer progression
Danhua LI ; Bin ZHANG ; Xuchen CAO
Journal of International Oncology 2013;(1):18-21
CD44 has been the subject of extensive research because of its role in cancer and many physiological processes.Through binding to different ligands,CD44 can initiate a series of cascade.CD44 not only can promote tumorigenic and tumor metastasis,but also can suppress tumor growth and progression.In-depth study of CD44 and its role in signal pathway may provide a new path for cancer treatment.
3.Runx2 and tumor metastasis
Wenwen GENG ; Bin ZHANG ; Xuchen CAO
Journal of International Oncology 2012;(12):892-894
Runt-related transcription factor 2 (Runx2) is a nuclear transcription factor of PEBP2/CBF superfamilies,and can regulate matrix metalloproteinase (MMP),osteopontin (OPN) and bone sialoprotein (BSP) which are associated with the metastasis of tumors including breast cancer and prostate cancer.In these cancers,the expression of Runx2 is highly up-regulated,which is closely correlated with the cell transformation and tumor progress.Lots of studies have demonstrated that the function of Runx2 is involved in several signal pathways activation,which can promote the early metastasis of malignant tumors.Therefore,the treatment targeting to Runx2 may be a new clinically choice to block the metastasis of tumors in the future.
4.Progress in dendritic cells immunotherapy
Bowen LIU ; Bin ZHANG ; Xuchen CAO
Journal of International Oncology 2011;38(1):20-23
Cancer immunotherapy is a new approach to cancer treatment. Dendritic cells, the most potent antigen-presenting cells found in humans, have attracted a lot of researches. However, dendritic cells are insufficient to cross-present self-antigens in-vivo. To improve the dendritic cells' antigen-presenting capabilities and the anti-tumor effect, in vitro preparation of dendritic cell vaccine and combination with pro-apoptotic treatments such as chemotherapy are being used.
5.Autophagy and cancer therapy
Zujin CHEN ; Bin ZHANG ; Xuchen CAO
Journal of International Oncology 2011;38(3):170-173
Autophagy is an evolutionarily conserved lysosomal pathway for the degradation of cytoplasmic proteins,macromolecules,and organelles.Now,autophagic cell death is considered as programmed cell death type Ⅱ.In multiple studies,inhibition of autophagy will result in contrasting outcomes-survival or death.Thus,whether autophagy in cancer cells causes death or protects cells is controversial.Taken together,the manipulation of autophagy may lead to development of new cancer therapies.This article focuses on recent progresses of autophagy research related to human cancers therapy.
6.Histone deacetylase inhibitors in cancer therapy
Yuanyuan LI ; Bin ZHANG ; Xuchen CAO
Journal of International Oncology 2011;38(6):424-427
The acetylation status of histories regulates access of transcription factors to DNA and influences levels of gene expression.Histone deacetylase(HDAC)activity diminishes acctylation of histones,causing compaction of the DNA-histone complex.This compaction blocks gene transcription and inhibits cell differentiation.HDAC inhibitom decompact the DNA-histone complex and promote cell growth arrest,differentiation,and apoptosis of tumor cells.Meantime,HDAC inhibition also affects acetylation status and function of non-histone proteins.HDAC inhibitors not only possess significant anti-tumor effects with single use,but also has great significance in combined therapy with other drugs.
7.Epithelial-mesenchymal transition and breast cancer
Weihong FENG ; Bin ZHANG ; Xuchen CAO
Journal of International Oncology 2011;38(2):121-123
Epithelial-mesenchymal transition cause primary carcinoma cells to acquire mesenchymal features and re-epithelialize to form a secondary mass at a metastatic site. Such plasticity has implications in the progression of breast carcinoma to metastasis, and will likely influence cancer's response to therapy. The transcriptional and epigenetic regulation that underlie the development of breast cancer and result in characteristic changes in cell behavior can be monitored using an array of marker proteins, providing the potential for emergent prognostic and therapeutic targeting.
8.Investigation of temporomandibular joint space of healthy adults by using cone beam computed tomography
Ruiyong WANG ; Xuchen MA ; Wanlin ZHANG ; Denggao LIU
Journal of Peking University(Health Sciences) 2003;0(05):-
0.05).Conclusion:All the results of the five measurement methods showed that the condyle was located in the center of the fossa with a variation in the healthy adults in intercuspal position.The CBCT image of the sagittal middle layer of the joint could show the joint space accurately and has an important value in the research related to the changes of TMJ space.
9.Role of Runx2 in Breast Cancer
Yao TIAN ; Lu CHEN ; Bin ZHANG ; Xuchen CAO
Tianjin Medical Journal 2014;(8):840-842
Runx2 is a transcription factor belongs to RUNXX family, and it is one of the important factors involved in expression and participation in regulation of mammary specific genes in the mammary gland. The overexpression is also as-sociated with certain characteristics of breast cancer. This article aims to summarize the recent progress of the role that Runx2 plays in breast cancer.
10.Clinicopathological characteristics and prognosis of lung metastases from breast cancer
Danhua LI ; Bin ZHANG ; Wenwen GENG ; Xinrui LIANG ; Xuchen CAO
Chinese Journal of General Surgery 2013;(2):96-99
Objective To investigate the clinicopathological characteristics and prognosis of lung metastases from breast cancer.Methods The clinical data of 119 breast cancer patients treated at our institution from January 2000 to January 2007 were retrospectively reviewed.Results Among 119 patients with lung metastasis,35.3% was hormone receptor (HR) +/human epithelial growth factor receptor (HER2)-,17.6% was HR +/HER2 +,21.8% was HR-/HER2 + and 25.2% was trriple negative breast cancer (TNBC).The rate of grade Ⅲ in triple negative breast cancer was higher than the other subtypes(P =0.016).The median overall survival was 60 months (9-141 months),the median time to lung metastases was 29 months (3-99 months),and the median survival after lung metastasis was 33 months (range,6-98 months).The 1-,2-,3-and 5-year survival rate was 72.9%,54.1%,35.1% and 14.4%.Conclusions TNBC,number of lung metastases,time to lung metastases less than 24 months,and a history of systemic chemotherapy were important factors for prognosis of patients with lung metastases.